Danavorexton

Danavorexton (developmental code name TAK-925) is a selective orexin 2 receptor agonist.^[1] It is a small-molecule compound and is administered intravenously.^[1][2] The compound was found to dose-dependently produce wakefulness to a similar degree as modafinil in a phase 1 clinical trial.^[1][3] As of March 2021, danavorexton is under development for the treatment of narcolepsy, idiopathic hypersomnia, and sleep apnea.^[2][1][4] It is related to another orexin receptor agonist, firazorexton (TAK-994), the development of which was discontinued for safety reasons in October 2021.^[1][5]

Other namesTAK-925

Routes of
administrationIntravenous^[1][2]

Drug classOrexin receptor agonist

Elimination half-life~3.3–5.1 h

Quick facts Clinical data, Other names ...

Danavorexton

Clinical data
Other names	TAK-925
Routes of administration	Intravenous[1][2]
Drug class	Orexin receptor agonist
Pharmacokinetic data
Elimination half-life	~3.3–5.1 h
Identifiers
IUPAC name methyl (2R,3S)-3-(methanesulfonamido)-2-[(cis-4-phenylcyclohexyl)oxymethyl]piperidine-1-carboxylate
CAS Number	2114324-48-8
PubChem CID	130310079
ChemSpider	68011464
UNII	1QMD83K4YN
ChEMBL	ChEMBL4650341
PDB ligand	A6F (PDBe, RCSB PDB)
CompTox Dashboard (EPA)	DTXSID401336757
Chemical and physical data
Formula	C21H32N2O5S
Molar mass	424.56 g·mol−1
3D model (JSmol)	Interactive image
SMILES COC(=O)N1CCC[C@H](NS(C)(=O)=O)[C@@H]1CO[C@H]1CC[C@H](CC1)C1=CC=CC=C1
InChI InChI=1S/C21H32N2O5S/c1-27-21(24)23-14-6-9-19(22-29(2,25)26)20(23)15-28-18-12-10-17(11-13-18)16-7-4-3-5-8-16/h3-5,7-8,17-20,22H,6,9-15H2,1-2H3/t17-,18+,19-,20-/m0/s1 Key:UXZAJSZFFARTEI-YRPNKDGESA-N

Close